Always a pleasure learning from @szusmani present his ground breaking research @ASCO Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible pts in ph 3
CEPHEUS study
Always a pleasure watching my former mentor @szusmani at @ASH_hematology presenting data for a Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma:DREAMM-9 Updated Interim Analysis”
#curemyeloma